Core Insights - The recent clinical trial results for LuX-ValvePlus and JensClip were presented at EuroPCR 2025, highlighting their safety and efficacy in treating severe tricuspid and mitral valve regurgitation [1][2] Group 1: LuX-ValvePlus - The TRINITY trial is a global, prospective, multi-center, single-arm clinical study assessing the safety and efficacy of LuX-ValvePlus in high-risk patients with severe tricuspid regurgitation [1] - The study included 161 patients from 20 centers worldwide, primarily from France, Germany, Spain, Denmark, and the UK [1] - The 30-day follow-up results demonstrated good safety and efficacy, with a low incidence of adverse events and improved quality of life for patients [1] - LuX-ValvePlus offers an excellent treatment option for patients with severe tricuspid regurgitation, particularly for those with large annuli, where treatment options are currently limited [1] - Long-term follow-up data and FDA clinical research data for LuX-ValvePlus are still being collected [1] Group 2: JensClip - JensClip is an innovative medical device designed for the treatment of severe mitral valve regurgitation, noted for its ease of use and reliability [2] - The one-year follow-up results showed a low all-cause mortality rate of only 1.8%, with minimal device-related complications [2] - 96.3% of patients exhibited no moderate or severe regurgitation, along with sustained improvements in various clinical metrics such as NYHA functional class, Kansas City Cardiomyopathy Questionnaire scores, and six-minute walk distance [2]
健世科技-B(09877)：LUX-VALVE PLUS TRINITY研究及JENSCLIP临床研究随访结果于EUROPCR 2025发布，展现良好的安全性和疗效表现